Background: To study the variability in the request of serum uric acid (SUA) in primary care.
Traditionally, the request of serum uric acid laboratory test (SUA) is indicated with presence of symptoms of gout, since treatment is not recommended in cases of asymptomatic hyperuricemia. 2 However, recent studies using dual-energy CT (DECT) have demonstrated urate deposits in hyperuricaemic patients without a previous acute episode of joint inflammation. 3 On the other hand, current guidelines for the management of gout 4, 5 advise starting urate-lowering therapies for patients with tophi.
In 2008 an over-request of SUA was identified in primary care in the Valencia Autonomous Community 6 in Spain. 6, 7 A strategy to improve the request for SUA in primary care, 8 evaluated through process and outcome appropriateness indicators, 9 resulted in a decrease in SUA measurement and allopurinol prescription. This would avoid the risk of treating asymptomatic patients. We hypothesized that the number of SUA tests requested from primary care is quite heterogeneous among the different Spanish regions and the inclusion of this test in profiles could modify its demand.
The aim was to study the request for SUA from primary care in Spain, the regional variability, and potential root causes of requesting patterns.
Materials and Methods
A cross-sectional study was designed and a call for data was posted via email. Spanish laboratories were invited to fill out an enrollment form: the number of SUA and serum glucose (SG) requested for 2014 by all GPs. SUA test-utilization rate was calculated as ratio of SUA to SG request (SUA/SG), as in Spain SG is included in every primary care profile and is the most requested laboratory test in primary care. 12, 13 In November 2016, a survey was sent to each participant regarding on the inclusion of SUA in laboratory panels during 2014, and specifically in a health check profile, a group of tests used in primary care in Spain as a screening to check for the most prevalent conditions, used for many patients presenting with non-specific symptoms.
The National Public Health System is composed by 17 regions called Autonomous Communities (AACCs) with Health Departments (HDs) that cover a population, and have several primary care centers and usually a unique hospital with a laboratory that attends the needs of every inhabitant. Laboratories were grouped in the different AACCs, when there were more than 4 participants, and a group joined the results of the rest. AACCs were codified by numbers because of confidentiality. SUA/SG was compared between the different AACCs and also between HDs with SUA included and not included in the health check profile. 1  3  5  7  9  11  13  15  17  19  21  23  25  27  29  31  33  35  37  39  41  43  45  47  49  51  53  55  57  59  61  63  65  67  69  71  73  75  77  79  81  83  85  87  89  91  93  95  97  99  101  103 Figure 1 shows the SUA/SG indicator in every HD; it was 7-fold times higher in some laboratories than others. Out of the 110 participants, 41 had a SUA/SG over 0.9, ie similar request for SUA and SG in primary care.
10 AACCs (in alphabetical order: Andalucía, Canarias, Castilla La Mancha, Castilla Leon, Extremadura, Galicia, Madrid, Murcia, País Vasco and Valencia), had more than 4 participant laboratories. An eleventh group brought together the results of the other 5 AACCs (in alphabetical order: Aragon, Asturias, Baleares, Cantabria and Cataluña). There was a high, significant (P = .008) regional variability in the SUA/SG ratio. In one AACC, both tests were systematically requested together (Figure 2) .
Out of the 110 participants, 47 laboratories (59.1%) completed the survey, and 80% of laboratories were involved in profiles design. SUA was included in at least 1 profile in 79.1% of cases (in 35.1% of cases SUA was included in 1 profile, in 27.1% in 2, in 13.5% in 3 and 4, and in 5.4% in 5 and more of 5 profiles).
In 53.6% of participants, SUA was included in the health check profile, and those laboratories had significantly (P = .003) higher SUA/SG ratios than those that did not (0.92 SUA/SG, IQR 0.20 vs. 0.69 SUA/SG, IQR 0.34).
Discussion
There were significant regional differences in the request of SUA in primary care in Spain, and an overall apparent over-request of SUA. The latter seems to be related to different habits between regions or the inclusion of SUA in order panels, as SUA was included in at least 1 profile in 80% of laboratories, and the demand was higher in those where the test was included in the health check profile. In fact, 66.7% of centers that have a SUA/SG ratio between 0.2 and 0.6 do not have SUA included in the health check profile. On the contrary, in 62.7% of the centers with a ratio between 0.6 and 1.00, SUA is part of the profile.
Despite the fact that SUA might be useful for the assessment of metabolic syndrome, 14 the test is still only used in primary care in Spain when gout is suspected. The second indication is to monitor patients that undergo chemotherapy or radiation treatments. 15 As cancer patients are not treated in primary care in Spain, the indication of its request is limited to the diagnosis and management of gout, to monitor its reduction over time to sub-saturating levels in order to prevent or even reverse the formation and deposition of urate crystals.
However, the results of our study show a high variability and similar requests to previous REDCONLAB 10,11 studies. Furthermore, requests were very close to that of SG, showing a high rate of utilization even when not part of the health check profiles, indicating a high demand for a test with such a specific indication, gout disease, which is not one of the most frequent indications for requesting laboratory tests in primary care. 16 In that scenario, there is a risk to detect "asymptomatic hyperuricemia," which does not require treatment. 17, 18 The different request between AACCs, could suggest different habits. However, the inclusion of the test in profiles in 80% of laboratories, and the different results obtained when SUA was part of the health check profile, suggest that order panels could also contribute to SUA over-request. 19 There is probably need to remove SUA from primary care profiles and to promote the intervention of laboratory professional, in the design of laboratory batteries. 20 Our study had certain limitations. First, it might be difficult to generalize our results to non-public environments, with no population or specific inhabitants to cover. Second, removing SUA from panels may result in misdiagnosis of gout in a patients needing the test; however, GPs could always order SUA individually if presenting with gout symptoms.
There was a high request of SUA in primary care and significant differences between regions. Regional customs or habits and the inclusion of the test in laboratory profiles might have contributed to the observed demand. Initiatives for a standardized request of SUA in primary care should be designed 8 and developed between GPs, rheumatologists, and laboratory professionals, for the best use of SUA in primary care patients. LM
